Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Additional Reading from MarketBeat The 2026 Cannabis Wildcard: How Tax Reform Could Reset Stock ValuationsAuthored by Jeffrey Neal Johnson. First Published: 12/30/2025. 
Quick Look - The removal of punitive federal tax codes would allow cannabis operators to deduct standard business expenses and finally generate sustainable free cash flow.
- Canopy Growth has successfully transitioned to an asset-light business model while securing strategic assets to trigger immediate entry into the American market.
- Tilray Brands leverages a robust craft beverage division to ensure financial stability and growth while maintaining a global footprint in the medical cannabis sector.
As the trading year 2025 draws to a close, the cannabis sector presents a confusing picture for many investors. On Dec. 18, 2025, President Trump signed a pivotal Executive Order directing the Attorney General to expedite the rescheduling of cannabis. By conventional measures, that political milestone should have sparked a sustained rally. Instead, the market reacted with a sharp sell-the-news correction. Nvidia's latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 trillion calculations per second. Elon Musk and Nvidia's Jensen Huang are now teaming up to deploy one million of these chips inside what could become the most advanced AI machine on the planet.
But according to James Altucher, the real opportunity isn't in Tesla or Nvidia. He's uncovered a little-known company that Musk, Nvidia, and even 98% of the Fortune 500 already rely on to make AI 2.0 possible. Nvidia's CEO has even called this company "essential" to their expansion. See how to invest in this revolutionary AI supplier here Leading equities in the space have retreated significantly and are trading near year-to-date lows. This price action suggests a market that has grown exhausted. Investors, tired after years of bureaucratic delays and false starts, largely ignored the longer-term implications of the order and focused on the lack of immediate, overnight legalization. However, many analysts view the current pessimism as a contrarian opportunity. The market is pricing cannabis stocks as if regulatory reform has already failed, even though evidence points to a concrete regulatory shift in 2026. That disconnect between depressed valuations and improving political probabilities has created an oversold condition. While the crowd is selling, the fundamental setup for 2026 suggests the sector could be positioned for a meaningful reversal. The Macro Catalyst: From Red Tape to Green Cash The potential turnaround in 2026 comes down to tax law. The wildcard scenario depends on moving cannabis from Schedule I to Schedule III under the Controlled Substances Act. While that may sound administrative, it would effectively operate as a large corporate tax cut for the industry. Today, U.S. cannabis operators (and firms preparing to enter the market) are constrained by IRS Section 280E, which prevents businesses trafficking in Schedule I or II substances from deducting standard business expenses. - The Current Problem: A typical business deducts rent, payroll, and utilities from revenue before calculating taxes. Cannabis companies cannot. They are taxed on gross profit, often resulting in effective tax rates of 70% or more, which severely limits cash flow.
- The 2026 Solution: If cannabis moves to Schedule III, Section 280E would no longer apply. Companies could immediately deduct ordinary operating costs.
For the stock market, this is the critical variable. Removing 280E would change the industry's financial model, shifting many companies from burning cash to generating free cash flow. If the December Executive Order leads to a finalized rule in 2026, valuations would likely reset to reflect this more profitable reality. Canopy Growth Corporation: The Aggressive U.S. Bet For investors seeking aggressive exposure to a potential U.S. market opening, Canopy Growth Corporation (NASDAQ: CGC) remains a primary vehicle. The company has spent the past two years reshaping its business into an asset-light model, divesting heavy cultivation facilities to cut overhead and preserve capital. Canopy’s thesis centers on Canopy USA. This structure lets the company hold economic interests in U.S. assets while maintaining compliance with NASDAQ rules. The strategy is binary: if federal rescheduling permits, Canopy USA could complete acquisitions of those U.S. entities, immediately consolidating their revenue. While waiting for Washington to act, Canopy has continued to execute operationally. On Dec. 15, 2025, the company announced the strategic acquisition of MTL Cannabis. - Supply Chain Security: The deal secures a consistent, high-quality flower supply, which is critical for maintaining market share in Canada.
- Export Capability: MTL boosts Canopy's ability to serve international medical markets, providing a revenue bridge while the U.S. strategy develops.
Combined with a cost-reduction program delivering roughly $21 million in annualized savings, Canopy is positioned to survive current volatility and scale quickly once the regulatory environment shifts. Tilray Brands: The Diversified Fortress Tilray Brands, Inc. (NASDAQ: TLRY) offers a different value proposition, prioritizing stability through diversification. Rather than hinging the entire company on a single regulatory outcome, Tilray operates on three pillars: Cannabis, Wellness, and Beverage Alcohol. If political delays extend into 2026, Tilray has a built-in safety net. Following a series of 2024 acquisitions, the company has become the 5th-largest craft brewer in the U.S., owning recognizable brands such as Hop Valley and Terrapin. Revenue from craft beer and bourbon provides steady cash flow that insulates Tilray from cannabis-sector volatility. Additionally, Project 420 is designed to streamline operations and save millions across its beverage and cannabis lines. Management has also taken decisive steps to clean up the capital structure. On Dec. 1, 2025, Tilray executed a 1-for-10 reverse stock split. - Institutional Access: Many large institutional funds cannot buy stocks trading below $5. By increasing the share price, Tilray reopened the door to those investors.
- Compliance: The move preserves long-term NASDAQ compliance and removes the risk of delisting.
Tilray also maintains a strong European presence, holding a cultivation license under Germany’s new Cannabis Act. That international footprint allows it to grow revenue irrespective of U.S. timing. The Bear Trap: Anatomy of a Short Squeeze Both Canopy Growth and Tilray Brands are trading at historically low valuations relative to sales. Despite these bargain prices, short interest — the volume of shares borrowed by investors betting prices will fall — remains elevated. Those short sellers are effectively wagering that the federal government will fail to execute the rescheduling order, which creates a high-risk setup for the bears. - The Trap: If a positive announcement arrives — for example, the DEA publishing a final Schedule III rule — the rationale for shorting these stocks would evaporate.
- The Scramble: Short sellers would be forced to buy shares to cover positions and exit trades.
- The Squeeze: This forced buying can create a feedback loop: as shorts cover, the price rises, prompting more covering.
Because sentiment is so negative, even modest good news could trigger this chain reaction. Heavy short positioning acts like dry powder; a regulatory spark could ignite a rapid and violent upside move. 2026 Outlook: Time for Execution Where 2025 was defined by waiting, the landscape heading into 2026 has changed. Companies are leaner, cost structures are improved, and the President has issued a direct order aimed at cutting regulatory red tape. Investors now face a binary window. If the administration follows through, removing the 280E tax burden could justify materially higher stock prices. The sector has moved from hope to the possibility of execution. For those watching closely, current prices present clear risk but also a potential historic discount if the political wildcard plays out in the industry's favor.
| 
Post a Comment
Post a Comment